• Publications
  • Influence
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
Objectives:  Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM). However, there is limited data for the effect of LenDex on renal impairmentExpand
  • 62
  • 4
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with aExpand
  • 113
  • 3
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and
We prospectively studied the impact of several cytogenetic abnormalities (CAs) in patients with relapsed/refractory myeloma who received lenalidomide and dexamethasone (RD) with or without theExpand
  • 110
  • 3
Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk
The outcome of patients with multiple myeloma (MM) is heterogeneous and the median survival of patients with symptomatic disease ranges from a few months to several years. Although the survival of MMExpand
  • 3
  • 1
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
About 50% of newly diagnosed mutilple myeloma (MM) patients (NDMM) have some degree of renal impairment (RI) at presentation, up to 20% have severe acute kidney injury (AKI) and ~1–5% may requireExpand
  • 17
The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,
Abstract 3961 Renal impairment (RI) is a frequent complication of multiple myeloma (MM). Proteasome inhibitors and immunomodulatory drugs (IMiDs) are used as frontline therapy for MM but their effectExpand
  • 6
Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction
Severe renal impairment (RI) in MM patients is a medical emergency. Immediate antimyeloma therapy and appropriate supportive measures are needed because these patients are at high risk for earlyExpand
  • 2
Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy
Multiple Myeloma (MM) is a disease of the elderly and due to the aging population an increasing number of patients are diagnosed at the age ≥80 year. The management of these octogenarians isExpand
  • 6
Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment
Renal impairment (RI) is a frequent complication of multiple myeloma (MM) and is associated with significant morbidity and risk of early death. Patients with severe RI (eGFR 60 ml/min/1.73 m2, renalExpand
  • 3
Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important
Pomalidomide with low dose dexamethasone (Pd) is a standard treatment for patients who have failed both lenalidomide (Len) & bortezomib (Bor). Phase III studies showed that Pd is active irrespectiveExpand
  • 1